Rose Snipes

416 total citations
9 papers, 318 citations indexed

About

Rose Snipes is a scholar working on Hematology, Radiology, Nuclear Medicine and Imaging and Surgery. According to data from OpenAlex, Rose Snipes has authored 9 papers receiving a total of 318 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Hematology, 4 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Surgery. Recurrent topics in Rose Snipes's work include Platelet Disorders and Treatments (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Cancer, Lipids, and Metabolism (2 papers). Rose Snipes is often cited by papers focused on Platelet Disorders and Treatments (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Cancer, Lipids, and Metabolism (2 papers). Rose Snipes collaborates with scholars based in United States, United Kingdom and Poland. Rose Snipes's co-authors include Jennifer Christian, Kimberly A. Lowe, Ralph I. Horwitz, Bhakti Arondekar, Erin Buysman, Terry A. Jacobson, Peter Kießling, Isidro Jarque, Stephen Jolles and Tadeusz Robak and has published in prestigious journals such as Blood, PLoS ONE and The American Journal of Medicine.

In The Last Decade

Rose Snipes

9 papers receiving 309 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rose Snipes United States	7	132	125	86	62	59	9	318
I Aoki Japan	8	121 0.9×	96 0.8×	56 0.7×	77 1.2×	54 0.9×	29	325
Rosa M. Agra Spain	11	137 1.0×	264 2.1×	81 0.9×	55 0.9×	67 1.1×	16	400
Sara Haidermota United States	8	143 1.1×	90 0.7×	47 0.5×	60 1.0×	22 0.4×	20	310
Yoji Inishi Japan	10	57 0.4×	93 0.7×	61 0.7×	25 0.4×	29 0.5×	18	333
Lin Liao China	11	57 0.4×	58 0.5×	53 0.6×	37 0.6×	36 0.6×	22	313
Jacob Marsvin Laurberg Denmark	5	94 0.7×	103 0.8×	20 0.2×	20 0.3×	27 0.5×	5	319
Jessica Mann Switzerland	5	149 1.1×	238 1.9×	19 0.2×	40 0.6×	45 0.8×	6	401
Valeria Pecci Italy	7	77 0.6×	116 0.9×	29 0.3×	121 2.0×	202 3.4×	12	444
Addisalem Taye Makuria United States	8	172 1.3×	64 0.5×	41 0.5×	21 0.3×	104 1.8×	12	405
Margareth L. Venturinelli Brazil	5	229 1.7×	155 1.2×	21 0.2×	21 0.3×	103 1.7×	5	433

Countries citing papers authored by Rose Snipes

Since Specialization

Citations

This map shows the geographic impact of Rose Snipes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rose Snipes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rose Snipes more than expected).

Fields of papers citing papers by Rose Snipes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rose Snipes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rose Snipes. The network helps show where Rose Snipes may publish in the future.

Co-authorship network of co-authors of Rose Snipes

This figure shows the co-authorship network connecting the top 25 collaborators of Rose Snipes. A scholar is included among the top collaborators of Rose Snipes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rose Snipes. Rose Snipes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Cooper, Nichola, James B. Bussel, Maciej Kaźmierczak, et al.. (2024). Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double‐blind, placebo‐controlled phase 3 studies and their open‐label extension. British Journal of Haematology. 206(2). 675–688. 6 indexed citations

Robak, Tadeusz, Maciej Kaźmierczak, Isidro Jarque, et al.. (2020). Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. Blood Advances. 4(17). 4136–4146. 83 indexed citations

Robak, Tadeusz, Isidro Jarque, Jacek Treliński, et al.. (2019). S850 SAFETY AND EFFICACY OF AN ANTI‐FCRN ANTIBODY, ROZANOLIXIZUMAB, IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF A PHASE II, MULTIPLE‐DOSE STUDY. HemaSphere. 3(S1). 379–379. 3 indexed citations

Robak, Tadeusz, Maciej Kaźmierczak, Isidro Jarque, et al.. (2019). Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia. Blood. 134(Supplement_1). 897–897. 4 indexed citations

Robak, Tadeusz, Isidro Jarque, Peter Kießling, et al.. (2017). Phase II, Multiple-Dose Study of Anti-FcRn Antibody, Rozanolixizumab (UCB7665), in Patients with Primary Immune Thrombocytopenia: Interim Analysis. Blood. 130. 15–15. 11 indexed citations

Shi, Yi, Rose Snipes, Salim Janmohamed, et al.. (2014). Effect of Darapladib Treatment on Endarterectomy Carotid Plaque Lipoprotein-Associated Phospholipase A2 Activity: A Randomized, Controlled Trial. PLoS ONE. 9(2). e89034–e89034. 18 indexed citations

Christian, Jennifer, Bhakti Arondekar, Erin Buysman, et al.. (2013). Determining Triglyceride Reductions Needed for Clinical Impact in Severe Hypertriglyceridemia. The American Journal of Medicine. 127(1). 36–44.e1. 57 indexed citations

Christian, Jennifer, et al.. (2011). Prevalence of Severe (500 to 2,000 mg/dl) Hypertriglyceridemia in United States Adults. The American Journal of Cardiology. 107(6). 891–897. 117 indexed citations

Bays, Harold, Kevin C. Maki, James M. McKenney, et al.. (2010). Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. Current Medical Research and Opinion. 26(4). 907–915. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact